Ποια είναι η τιμή για Acorda Therapeutics, Inc. (ACOR)

Η τιμή για Acorda Therapeutics, Inc. (ACOR) είναι $0.879

Ποια είναι η κεφαλαιοποίηση αγοράς για Acorda Therapeutics, Inc. (ACOR)

Η κεφαλαιοποίηση αγοράς για Acorda Therapeutics, Inc. (ACOR) είναι $582.38K

Acorda Therapeutics, Inc. (ACOR) Τιμή και Κεφαλαιοποίηση Αγοράς

Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.

Η τιμή για ACOR	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$8,255,283 $582.38K	NVDA	$5.470T	+939,167,481.32%
$6,742,240 $582.38K	AAPL	$4.467T	+767,035,183.02%
$6,300,485 $582.38K	GOOG	$4.174T	+716,778,630.92%
$5,584,601 $582.38K	MSFT	$3.700T	+635,335,608.15%
$4,308,117 $582.38K	AMZN	$2.854T	+490,115,562.08%

Η τιμή για ACOR

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$8,255,283 $582.38K